Cited by 73Treatment of Major DepressionSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

A Review of Modern Antidepressants Effects on Neurocognitive Function

Biringer, Eva, Rongve, Arvid, Lund, Anders·2009·Current Psychiatry Reviews

Abstract

The present paper reviews the current literature on modern antidepressants effects on neurocognitive function. Today, it seems justified to state that SSRIs in general do not affect cognitive function. However, there exists some evidence that paroxetine is associated with a somewhat lower performance on neurocognitive tests than other sub-groups of SSRIs. Further, studies have consistently found sertraline to be better with regard to cognitive function compared to other SSRIs. There is a lack of studies assessing effects of RIMAs and α2-receptor antagonists on cognitive function. Some evidence suggests that the latter may have negative effects on cognitive function. Other studies suggest that reboxetine, bupropion and SNRIs may be more beneficial with regard to cognitive function than other antidepressants. However, the question whether these medications may actually improve cognitive function to a higher level than expected from improvement in depressive symptomatology, remains unclear. Clinical, social and emotional factors are important for cognitive function and these factors should always be taken into consideration when assessing effects of modern antidepressant therapy on cognitive function. Keywords: Antidepressant, cognition, SSRI, SNRI, bupropion, reboxetine

Integrity signals

Registry

Crossref · 10.2174/157340009788971137

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Few studies have evaluated the effect of antidepressants on non-emotional, objectively measured cognitive performance in non-elderly adults with MDD, and they generally have small sample size, are not placebo-controlled and assess treatment effect compared to baseline.

    “Studies are challenged by the heterogeneity of cognitive dysfunction and few studies have evaluated the effect of antidepressants on non-emotional, objectively measured cognitive performance in non-elderly, adults with MDD, and they generally have a small sample size, are not placebo-controlled and assess treatment effect compared to baseline (Biringer et al., 2009; McIntyre et al., 2013).”
  • Some evidence suggests sertraline and bupropion have superior neurocognitive enhancing effects compared to other serotonergic agents, and paroxetine is typically associated with worse neurocognitive outcomes.

    “Some evidence suggests that sertraline and bupropion have superior neurocognitive enhancing effects compared to other serotonergic agents (Baune and Renger, 2014;Biringer et al., 2009) and that the use of paroxetine is typically associated with worse neurocognitive outcomes (Biringer et al., 2009).”
  • Whether those medications improve neurocognitive function to a greater degree than expected from improvement in depressive symptomology is unclear.

    “Whether those medications improve neurocognitive function to a greater degree than expected from improvement in depressive symptomology is unclear (Biringer et al., 2009).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Biringer, E., Rongve, A., & Lund, A.
Affiliations
Fonna Hospital Trust (NO)
Corresponding author
Lund, Anders
Venue
Current Psychiatry Reviews
Published
2009-08-01
Volume
5
Issue
3
Pages
164-174
ISSN
1573-4005 (ISSN-L)
OpenAlex
W2160823555
Cited by
73
References
13
Citations by year
2026: 1 · 2025: 7 · 2024: 9 · 2023: 2 · 2021: 4 · 2020: 3 · 2018: 6 · 2017: 4 · 2016: 14 · 2015: 8 · 2014: 7 · 2013: 5 · 2012: 1
FWCI
0.72
Type
journal article
Language
en
Open access
closed
Locations
Current Psychiatry Reviews (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
antidepressants, neurocognitive function, selective serotonin reuptake inhibitors, paroxetine, sertraline, reboxetine, bupropion, serotonin-norepinephrine reuptake inhibitors, alpha2-adrenoceptor antagonists, cognitive side effects, depression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review